
Nature Medicine retracts morning dosing cancer claim after editors lose confidence
A clinical trial tied to “morning” effectiveness drew scrutiny, and the journal now signals integrity problems with the results.

Curating from trusted global sources…
Curated from trusted global sources, refined into briefing-grade analysis with executive summaries, insights, and bullet-point takeaways.

A clinical trial tied to “morning” effectiveness drew scrutiny, and the journal now signals integrity problems with the results.

A fan speedrunner showed native Windows 11 gameplay, using OpenPETE decomp plus recomp hybrid, with console-accurate quirks.

The shift to agentic work is surging across legal, recruiting, and beyond, with real token and productivity implications.

Herman Hulst confirms layoffs affecting most Destiny and some Marathon teams after Bungie admits Destiny fell short.

The chip giant filed for a Nasdaq listing plan that could raise $29.4 billion, instantly reshaping investor expectations.

Fiscal Q3 results crush estimates, prove AI memory is rewriting Micron's margins, and change the momentum math for the whole chip stack.

The satellite and rocket company’s quick $25 billion borrowing move signals how it plans to finance scale after going public.

On Thursday, Accenture hit its biggest one-day drop on record after forecasting worries that AI could hollow out consulting.

CNBC says SpaceX’s shares surge following its IPO Friday, forcing investors to reprice what “space” and “AI” are worth.

Big IPO, bigger options debut: what it means for investors, risk teams, and anyone benchmarking market appetite.

SpaceX exercised its option for Cursor in an all-stock deal worth $60 billion, reshaping AI dealmaking expectations.

The valuation jump of $1T in a single day changes the reference point for risk capital and public-market comps.